Pet NGF Therapeutic Antibody Development
Creative Biolabs drives innovation in veterinary biotechnology by developing therapeutic antibody programs tailored to the unique health challenges of companion animals. Our focus on nerve growth factor (NGF) as a therapeutic target reflects its central role in pain signaling pathways, particularly in chronic conditions that impact the quality of life for dogs and cats. By combining advanced discovery platforms, comprehensive characterization, and end-to-end development services, we help clients translate cutting-edge science into practical solutions for managing pain and improving animal welfare. If you are considering NGF-targeted therapies for pets, our team offers the expertise and resources to accelerate your goals.
Platforms in Therapeutic Antibody Discovery
We provide access to multiple discovery platforms that generate high-quality canine- and feline-specific antibodies for NGF inhibition. Each platform offers distinct advantages, and our team at Creative Biolabs can help clients select or integrate the most suitable approach to maximize success. If you are exploring NGF-focused antibody discovery, we encourage you to connect with us for tailored project planning.
- Phage Display: Our specialized phage libraries allow rapid screening of diverse antibody candidates with species-relevant binding profiles. This technology supports the identification of NGF-targeting antibodies optimized for efficacy and safety in pets.
- Single-B Cell Sorting: By isolating NGF-specific B cells from immunized animals, this platform yields naturally paired heavy and light chain sequences that preserve native diversity. The resulting antibodies are well-suited for downstream optimization, engineering, and functional testing.
- Hybridoma Technology: A proven method for generating monoclonal antibodies, hybridomas provide a stable source of candidates that can be further engineered for enhanced activity, durability, and reduced immunogenicity in companion animals.
Comprehensive Antibody Development Services
Our workflow covers the entire therapeutic antibody lifecycle, providing seamless support from concept to preclinical validation. These services ensure that NGF antibody candidates advance efficiently and with strong scientific foundations. If your pipeline requires high-quality characterization or translational evaluation, our team is ready to support your next steps.
Antibody Characterization
We deliver detailed analyses of binding kinetics, specificity, stability, and bioactivity to confirm candidate quality.
Antibody Engineering
Our team refines antibodies for enhanced pharmacological properties, including higher affinity, optimized Fc functions, and minimized immunogenic risk in canine and feline systems.
Preclinical Evaluation
Through rigorous in in vitro and in vivo models, we establish safety, pharmacokinetics, and therapeutic efficacy, ensuring robust data for informed decision-making.
Antibody Development
We offer scalable expression systems, purification, and quality control to deliver clinical-grade material ready for veterinary translational research.
Why Focus on NGF?
Nerve growth factor (NGF) is a neurotrophin critical for neuronal development and survival, but in adult animals, it becomes a central mediator of chronic pain. Elevated NGF levels are strongly associated with degenerative joint disease in dogs, including osteoarthritis, as well as painful oral conditions such as stomatitis in cats. By binding to its receptor TrkA on sensory neurons, NGF amplifies pain signaling pathways, leading to heightened sensitivity and persistent discomfort. Targeting NGF with therapeutic antibodies offers a powerful strategy to reduce pain in both species, improving mobility in dogs with arthritis and quality of life in cats suffering from chronic inflammatory pain.
Mechanism of Action
NGF-targeting antibodies work by binding to circulating NGF, preventing its interaction with the TrkA receptor on nociceptive neurons. This blockade interrupts the signaling cascade responsible for neuronal sensitization and pain amplification. As a result, pain perception decreases, mobility improves, and animals experience enhanced comfort without the side effects commonly associated with traditional analgesics. By modulating a key upstream mediator of pain rather than downstream symptoms, NGF antibody therapy represents a disease-modifying approach to managing chronic pain in companion animals.
Fig 1. Functional assays of caninized anti-NGF recombinant antibodies.1
Our Advantages
Partner with Creative Biolabs
The need for innovative pain management solutions in veterinary medicine is growing rapidly, and NGF-targeted antibody therapies represent one of the most promising frontiers. Creative Biolabs is dedicated to supporting clients with comprehensive discovery, engineering, and preclinical services tailored to canine and feline health. Whether you are initiating an NGF project or advancing an existing candidate, our team is ready to provide the expertise and infrastructure needed for success. Partner with us today to explore how NGF antibody development can advance your pipeline and improve the lives of companion animals.
Reference
- Gearing, David P et al. "A fully caninised anti-NGF monoclonal antibody for pain relief in dogs." BMC veterinary research vol. 9 226. 9 Nov. 2013. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/1746-6148-9-226